small nucleolar RNA, H/ACA box 71AGenealiases: RNU71A · U71a
Q-omics provides the consensus-scored SNORA71A profile across patient tissues and cancer cell-line models. SNORA71A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNORA71A is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SNORA71A RNA expression shows 16,104 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, and UVM as cancer lineages where SNORA71A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA71A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA71A survival associations across molecular data types. SNORA71A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA71A RNA expression–survival associations across cancer types. High SNORA71A expression shows unfavorable associations in COAD, KIRC, ACC, LGG and KIRP, but favorable associations in BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SNORA71A RNA expression.
This table summarizes SNORA71A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA71A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA71A shows higher tumor expression in COAD, LUSC, STAD, LUAD, HNSC and READ. The COAD box plot shows higher SNORA71A RNA expression in tumor versus normal tissue (log2 FC = +2.695, t-test p < 0.001).
This table shows molecular features associated with SNORA71A in patient tissues and cancer cell lines. In patient samples, SNORA71A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
